Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial.
J Infect Dis
; 2023 Nov 16.
Article
in En
| MEDLINE
| ID: mdl-37970668
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Infect Dis
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: